SANGAMO THERAPEUTICS, INC. Net Income (Loss) Available to Common Stockholders, Diluted
SANGAMO THERAPEUTICS, INC. (SGMOQ) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$53.16 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2022-11-03
- SANGAMO THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2022-09-30 was -$53.16M.
- SANGAMO THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2022-06-30 was -$43.17M.
- SANGAMO THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2021-09-30 was -$47.69M.
- SANGAMO THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2021-06-30 was -$47.17M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month |
|---|---|---|---|
| 2022-09-30 | -$53.16M 10-Q · filed 2022-11-03 | -$96.33M derived: sum of 2 quarters · filed 2022-11-03 | -$140.31M 10-Q · filed 2022-11-03 |
| 2022-06-30 | -$43.17M 10-Q · filed 2022-08-04 | -$87.15M 10-Q · filed 2022-08-04 | |
| 2021-09-30 | -$47.69M 10-Q · filed 2022-11-03 | -$94.86M derived: sum of 2 quarters · filed 2022-11-03 | -$140.79M 10-Q · filed 2022-11-03 |
| 2021-06-30 | -$47.17M 10-Q · filed 2022-08-04 | -$93.10M 10-Q · filed 2022-08-04 |